Literature DB >> 24744587

Post-infectious irritable bowel syndrome: mechanistic insights into chronic disturbances following enteric infection.

Jennifer K Beatty1, Amol Bhargava1, Andre G Buret1.   

Abstract

Irritable bowel syndrome (IBS) is a commonly encountered chronic functional gastrointestinal (GI) disorder. Approximately 10% of IBS patients can trace the onset of their symptoms to a previous a bout of infectious dysentery. The appearance of new IBS symptoms following an infectious event is defined as post-infectious-IBS. Indeed, with the World Health Organization estimating between 2 and 4 billion cases annually, infectious diarrheal disease represents an incredible international healthcare burden. Additionally, compounding evidence suggests many commonly encountered enteropathogens as unique triggers behind IBS symptom generation and underlying pathophysiological features. A growing body of work provides evidence supporting a role for pathogen-mediated modifications in the resident intestinal microbiota, epithelial barrier integrity, effector cell functions, and innate and adaptive immune features, all proposed physiological manifestations that can underlie GI abnormalities in IBS. Enteric pathogens must employ a vast array of machinery to evade host protective immune mechanisms, and illicit successful infections. Consequently, the impact of infectious events on host physiology can be multidimensional in terms of anatomical location, functional scope, and duration. This review offers a unique discussion of the mechanisms employed by many commonly encountered enteric pathogens that cause acute disease, but may also lead to the establishment of chronic GI dysfunction compatible with IBS.

Entities:  

Keywords:  Enteric pathogen; Immune alterations; Infectious diarrhea; Inflammatory disorders; Post-infectious irritable bowel syndrome

Mesh:

Substances:

Year:  2014        PMID: 24744587      PMCID: PMC3983453          DOI: 10.3748/wjg.v20.i14.3976

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  100 in total

1.  [The development of irritable bowel syndrome after Shigella infection: 3 year follow-up study].

Authors:  Hee Sun Kim; Min Su Kim; Sang Won Ji; Hyojin Park
Journal:  Korean J Gastroenterol       Date:  2006-04

2.  Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis.

Authors:  Alexandra-Chloé Villani; Mathieu Lemire; Marroon Thabane; Alexandre Belisle; Geneviève Geneau; Amit X Garg; William F Clark; Paul Moayyedi; Stephen M Collins; Denis Franchimont; John K Marshall
Journal:  Gastroenterology       Date:  2010-01-04       Impact factor: 22.682

Review 3.  New insights into visceral hypersensitivity--clinical implications in IBS.

Authors:  QiQi Zhou; G Nicholas Verne
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-06       Impact factor: 46.802

Review 4.  Systematic review of animal models of post-infectious/post-inflammatory irritable bowel syndrome.

Authors:  Hong-Yan Qin; Justin C Y Wu; Xu-Dong Tong; Joseph J Y Sung; Hong-Xi Xu; Zhao-Xiang Bian
Journal:  J Gastroenterol       Date:  2010-09-17       Impact factor: 7.527

5.  Role for protease activity in visceral pain in irritable bowel syndrome.

Authors:  Nicolas Cenac; Christopher N Andrews; Marinella Holzhausen; Kevin Chapman; Graeme Cottrell; Patricia Andrade-Gordon; Martin Steinhoff; Giovanni Barbara; Paul Beck; Nigel W Bunnett; Keith A Sharkey; Jose Geraldo P Ferraz; Eldon Shaffer; Nathalie Vergnolle
Journal:  J Clin Invest       Date:  2007-02-15       Impact factor: 14.808

6.  Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms.

Authors:  Cesare Cremon; Luciana Gargano; Antonio M Morselli-Labate; Donatella Santini; Rosanna F Cogliandro; Roberto De Giorgio; Vincenzo Stanghellini; Roberto Corinaldesi; Giovanni Barbara
Journal:  Am J Gastroenterol       Date:  2009-01-13       Impact factor: 10.864

Review 7.  Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome.

Authors:  Anneke Rijnierse; Frans P Nijkamp; Aletta D Kraneveld
Journal:  Pharmacol Ther       Date:  2007-07-18       Impact factor: 12.310

8.  Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis.

Authors:  L-H Wang; X-C Fang; G-Z Pan
Journal:  Gut       Date:  2004-08       Impact factor: 23.059

9.  Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity.

Authors:  K Gecse; R Róka; L Ferrier; M Leveque; H Eutamene; C Cartier; A Ait-Belgnaoui; A Rosztóczy; F Izbéki; J Fioramonti; T Wittmann; L Bueno
Journal:  Gut       Date:  2008-01-14       Impact factor: 23.059

10.  Correlation between gastrointestinal hormones and anxiety-depressive states in irritable bowel syndrome.

Authors:  Baojuan Han
Journal:  Exp Ther Med       Date:  2013-07-09       Impact factor: 2.447

View more
  29 in total

Review 1.  Inflammation in irritable bowel syndrome: Myth or new treatment target?

Authors:  Emanuele Sinagra; Giancarlo Pompei; Giovanni Tomasello; Francesco Cappello; Gaetano Cristian Morreale; Georgios Amvrosiadis; Francesca Rossi; Attilio Ignazio Lo Monte; Aroldo Gabriele Rizzo; Dario Raimondo
Journal:  World J Gastroenterol       Date:  2016-02-21       Impact factor: 5.742

2.  Colorectal distention induces acute and delayed visceral hypersensitivity: role of peripheral corticotropin-releasing factor and interleukin-1 in rats.

Authors:  Tsukasa Nozu; Shima Kumei; Saori Miyagishi; Kaoru Takakusaki; Toshikatsu Okumura
Journal:  J Gastroenterol       Date:  2015-03-26       Impact factor: 7.527

3.  Adherent-Invasive E. coli enhances colonic hypersensitivity and P2X receptors expression during post-infectious period.

Authors:  Amandine Lashermes; Ludivine Boudieu; Julie Barbier; Benoit Sion; Agathe Gelot; Nicolas Barnich; Denis Ardid; Frédéric Antonio Carvalho
Journal:  Gut Microbes       Date:  2017-10-04

Review 4.  Overlapping irritable bowel syndrome and inflammatory bowel disease: less to this than meets the eye?

Authors:  Eamonn M M Quigley
Journal:  Therap Adv Gastroenterol       Date:  2016-03       Impact factor: 4.409

Review 5.  Post-Infectious Irritable Bowel Syndrome.

Authors:  Yeong Yeh Lee; Chandramouli Annamalai; Satish S C Rao
Journal:  Curr Gastroenterol Rep       Date:  2017-09-25

6.  Clostridium difficile-related postinfectious IBS: a case of enteroglial microbiological stalking and/or the solution of a conundrum?

Authors:  Gabrio Bassotti; Lara Macchioni; Lanfranco Corazzi; Pierfrancesco Marconi; Katia Fettucciari
Journal:  Cell Mol Life Sci       Date:  2017-12-28       Impact factor: 9.261

Review 7.  Challenges in IBD Research: Environmental Triggers.

Authors:  Shuk-Mei Ho; James D Lewis; Emeran A Mayer; Scott E Plevy; Emil Chuang; Stephen M Rappaport; Kenneth Croitoru; Joshua R Korzenik; Jeffrey Krischer; Jeffrey S Hyams; Richard Judson; Manolis Kellis; Michael Jerrett; Gary W Miller; Melanie L Grant; Nataly Shtraizent; Gerard Honig; Andrés Hurtado-Lorenzo; Gary D Wu
Journal:  Inflamm Bowel Dis       Date:  2019-05-16       Impact factor: 5.325

8.  New and Emerging Treatment Options for Irritable Bowel Syndrome.

Authors:  Brian E Lacy; William D Chey; Anthony J Lembo
Journal:  Gastroenterol Hepatol (N Y)       Date:  2015-04

9.  Giardia duodenalis induces paracellular bacterial translocation and causes postinfectious visceral hypersensitivity.

Authors:  Marie C M Halliez; Jean-Paul Motta; Troy D Feener; Gaetan Guérin; Laetitia LeGoff; Arnaud François; Elodie Colasse; Loic Favennec; Gilles Gargala; Tamia K Lapointe; Christophe Altier; André G Buret
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-01-07       Impact factor: 4.052

10.  A High Rate of Alternative Diagnoses in Patients Referred for Presumed Clostridium difficile Infection.

Authors:  Melissa Jackson; Sidney Olefson; Jason T Machan; Colleen R Kelly
Journal:  J Clin Gastroenterol       Date:  2016-10       Impact factor: 3.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.